POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells

Duarte de Melo-Diogo, Elisabete C. Costa, Cátia G. Alves, Rita Lima-Sousa, Paula Ferreira, Ricardo O. Louro, Ilídio J. Correia

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.

Original languageEnglish
Pages (from-to)162-169
Number of pages8
JournalEuropean Journal of Pharmaceutics and Biopharmaceutics
Volume131
DOIs
Publication statusPublished - 1 Oct 2018

Fingerprint

Phototherapy
Graphite
Nanostructures
Oxides
Breast Neoplasms
alpha-Tocopherol
Doxorubicin
Therapeutic Uses
Drug Combinations
Neoplasms
Pharmaceutical Preparations
Ethylene Glycol
Polymers
Radiation
Therapeutics

Keywords

  • Cancer treatment
  • Co-delivery
  • Graphene oxide
  • Photothermal therapy
  • POxylation

Cite this

@article{9410b586446d4308a70b101551321cd5,
title = "POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells",
abstract = "PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.",
keywords = "Cancer treatment, Co-delivery, Graphene oxide, Photothermal therapy, POxylation",
author = "{de Melo-Diogo}, Duarte and Costa, {Elisabete C.} and Alves, {C{\'a}tia G.} and Rita Lima-Sousa and Paula Ferreira and Louro, {Ricardo O.} and Correia, {Il{\'i}dio J.}",
year = "2018",
month = "10",
day = "1",
doi = "10.1016/j.ejpb.2018.08.008",
language = "English",
volume = "131",
pages = "162--169",
journal = "European Journal of Pharmaceutics and Biopharmaceutics",
issn = "0939-6411",
publisher = "Elsevier Science B.V., Amsterdam.",

}

POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells. / de Melo-Diogo, Duarte; Costa, Elisabete C.; Alves, Cátia G.; Lima-Sousa, Rita; Ferreira, Paula; Louro, Ricardo O.; Correia, Ilídio J.

In: European Journal of Pharmaceutics and Biopharmaceutics, Vol. 131, 01.10.2018, p. 162-169.

Research output: Contribution to journalArticle

TY - JOUR

T1 - POxylated graphene oxide nanomaterials for combination chemo-phototherapy of breast cancer cells

AU - de Melo-Diogo, Duarte

AU - Costa, Elisabete C.

AU - Alves, Cátia G.

AU - Lima-Sousa, Rita

AU - Ferreira, Paula

AU - Louro, Ricardo O.

AU - Correia, Ilídio J.

PY - 2018/10/1

Y1 - 2018/10/1

N2 - PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.

AB - PEGylated graphene oxide (GO) nanomaterials have been showing promising results in cancer therapy, due to their drug loading and photothermal capacities. However, the recent reports regarding the immunogenicity of poly(ethylene glycol) based coatings highlight the importance of investigating alternative materials to functionalize GO. Herein, GO derivatives were functionalized for the first time with an amphiphilic polymer based on poly(2-ethyl-2-oxazoline) and were co-loaded with doxorubicin (DOX) and D-α-Tocopherol succinate (TOS) to be applied in chemo-phototherapy of breast cancer cells. The results revealed that POxylated GO displays the required properties for application in cancer therapy. Moreover, the screening of different DOX:TOS combination ratios showed that the 1:3 DOX:TOS molar ratio produces an optimal synergistic therapeutic effect towards breast cancer cells. Furthermore, this drug ratio had a lower impact on normal cells. POxylated GO was then loaded with this drug combination in order to assess its chemo-phototherapeutic potential. The delivery of DOX:TOS by POxylated GO to cancer cells induced a stronger therapeutic effect than that attained with the free drug combination. Furthermore, an even greater cytotoxicity towards cancer cells was achieved by exposing DOX:TOS loaded POxylated GO to near infrared radiation. Overall, POxylated GO is a promising drug delivery and phototherapeutic agent.

KW - Cancer treatment

KW - Co-delivery

KW - Graphene oxide

KW - Photothermal therapy

KW - POxylation

UR - http://www.scopus.com/inward/record.url?scp=85051808936&partnerID=8YFLogxK

U2 - 10.1016/j.ejpb.2018.08.008

DO - 10.1016/j.ejpb.2018.08.008

M3 - Article

VL - 131

SP - 162

EP - 169

JO - European Journal of Pharmaceutics and Biopharmaceutics

JF - European Journal of Pharmaceutics and Biopharmaceutics

SN - 0939-6411

ER -